PDF Cover

Self Injection Devices Market

The market for Self Injection Devices was estimated at $26.4 billion in 2025; it is anticipated to increase to $44.9 billion by 2030, with projections indicating growth to around $76.4 billion by 2035.

Report ID:DS1801099
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Self Injection Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Self Injection Devices Market Outlook

Revenue, 2025

$26.4B

Forecast, 2035

$76.4B

CAGR, 2026 - 2035

11.2%

The Self Injection Devices industry revenue is expected to be around $26.4 billion in 2026 and expected to showcase growth with 11.2% CAGR between 2026 and 2035. Growing demand for home based care, increasing need for chronic disease management and the expanding use of biologics, have contributed to Self Injection Devices playing a crucial role in patient centric drug delivery systems. Patients have fewer hospital visits with the help of these treatments which can be taken in the home. In addition they make patients stick to their therapy more and overall the treatments themselves are less expensive, especially when treating such diseases as cancer or those which are autoimmune. In the two fields cancer and autoimmune disease treatment, roughly 56% of the uses of treatments occur. The large revenue generated by disposable products in the market, $16.97 billion in 2025, indicates the significance placed on safety, convenience and infection control within the industry, thereby highlighting the ongoing relevance of self injection devices in treatment methods.

Self injection devices, also known as Autoinjector, are available in three forms, these include auto injectors, prefilled syringes and wearable injectors. All of these enable precise, controlled doses to be administered via subcutaneous injection, which requires minimal user training. Designs are ergonomically structured, and an enhanced safety mechanism has been incorporated to prevent needlestick injuries. Furthermore, various smart technologies now allow the electronic devices to connect with the internet, enabling patients to be reminded about the medication dose required and data from the devices to be shared with healthcare professionals. Conditions for which significant therapeutic benefit is anticipated include autoimmune disorders, cancer, metabolic and hormonal diseases, and other chronic illnesses which often require long term medication. The growing trend of patient self care and safety is stimulating demand for injectable drug delivery devices, particularly those which are single use and compact in design. New trends also include greater use of biological medicines in the smart home and clinic and the preference for devices that the patient can use unaided. Furthermore, the need for more compact devices is also a driving factor.

Self Injection Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Self Injection Devices Market Outlook

Market Key Insights

  • The Self Injection Devices market is projected to grow from $26.4 billion in 2025 to $76.4 billion in 2035. This represents a CAGR of 11.2%, reflecting rising demand across Diabetes Management, Vaccine Delivery, and Home Based Hormone Therapy.

  • Among the key players in this market are BD, Gerresheimer AG and Ypsomed. They are responsible for the competitive landscape that exists today.

  • The US and Germany have been found to be the most important markets for self injection devices. They will experience a compound annual growth rate of 8.2 % to 11.8 % from 2025 to 2030.

  • The highest growth is expected in emerging markets these are countries such as South Africa, India and Brazil. These markets will grow at a rate between 10.8% and 14% per year.

  • The advent of biologics is forecast to contribute a $4 billion growth stimulus to the sector for self injection devices by 2030.

  • The Self Injection Devices sector is forecast to increase by $50 billion in value over the period 2025 2030, with the Hospitals & Clinics Application category forecast to be the largest sector in this market.

  • With

    rising prevalence of chronic diseases and growing demand for home healthcare solutions, and

    Technological Advancements in Prefilled and Autoinjector Designs, Self Injection Devices market to expand 189% between 2025 and 2035.

self injection devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Self Injection Devices - Country Share Analysis

Opportunities in the Self Injection Devices

Despite the increasing rates of diabetes and obesity in India and Brazil, the market for self injection devices remains relatively untapped. Globally, pen injectors will generate $27.70 billion by 2030, rising from a 2025 figure of $16.97 billion. This growth of over 10.3% annually is also largely driven by pen injectors that administer insulin and GLP 1. Pen injectors with minimal invasiveness and their design will be the fastest growing products within the field of chronic disease management and home healthcare.

Growth Opportunities in North America and Asia-Pacific

In North America, self injection devices are mainly driven by the needs of patients suffering from auto immune disorders. This groups strong preference for using biologics at home by means of injection into the fatty tissue under the skin is driving demand for auto injectors and pens. There is potential for growth in premium connected devices for the injection of medication, platforms designed specifically for the self injection of cancer drugs and the services which combine training, data collection and support for patients on their treatment. In this highly competitive field where pharmaceutical companies team up with device manufacturers, firms entering the market must differentiate themselves through the use of ergonomically designed devices, safety features and tailor made programmes for specific treatments. Key drivers in the region include a well developed home healthcare infrastructure, the conversion of clinic based biologic infusions to home use for cancer and autoimmune diseases and robust reimbursement systems for self administered therapies.
The Asia Pacific region represents a key region for the use of self injection equipment. It is here that the self injection devices greatest advantages can be seen, particularly in the fields of endocrine and diabetes treatment. Here, switching from standard syringes to insulin and GLP 1 pens provides a significant scale benefit. Opportunities for strategic advancement in this region include the optimisation of costs, the local manufacture of the devices and the tailoring of device portfolios to meet the unique needs of biosimilars and the region. The market for handsets is highly fragmented with regional firms and contract manufacturers offering handsets with specific features at competitive prices. Consequently, major brands are now competing on value, supply reliability and partnerships with local drug companies rather than merely on the technological specifications of their products. Growing chronic disease prevalence, government run programmes to increase access to self administered treatments, increased spending by the expanding middle class on healthcare and the upgrade from standard injectables to user friendly auto injectors or pre filled syringes which support safer, more consistent self management in both urban and smaller town locations are the main drivers of regional growth.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Chronic Diseases and Growing Demand for Home Healthcare Solutions

The increasing prevalence of chronic diseases such as diabetes, multiple sclerosis, and hormone deficiencies is also a primary growth factor for self injection devices. Patients require frequent and precise administration of medications, which also drives adoption of prefilled pens and autoinjectors that ensure accurate dosing, reduce injection errors, and enhance adherence. Separately, the growing demand for home healthcare solutions is also transforming patient care by enabling treatments outside traditional clinical settings. Self injection devices empower patients to manage therapies conveniently at home, reducing hospital visits and associated costs. Together, these trends are also pushing manufacturers to innovate with ergonomic designs, digital tracking features, and smart connectivity, allowing remote monitoring of treatment adherence. Industry players like Novo Nordisk, BD, and Sanofi are also expanding offerings in smart insulin pens and connected autoinjectors, reflecting how both factors jointly contribute to accelerating market growth.
Rapid innovations in device engineering are also enhancing self injection convenience, safety, and patient compliance. Prefilled pens and autoinjectors now incorporate features like adjustable dosing, hidden needles, and digital reminders. These advancements reduce user errors, injection pain, and anxiety, particularly for pediatric and geriatric patients. Companies such as Eli Lilly and Amgen are also leveraging ergonomic designs and smart connectivity to track dosage data, creating opportunities for personalized therapy management. This technological evolution strengthens market adoption across home care, chronic disease management, and specialty therapy applications.
02

Restraint: High device cost and affordability limit patient access and healthcare adoption

The relatively high cost of advanced self injection devices, such as smart autoinjectors and prefilled pens with dose tracking, restricts uptake in both developed and emerging markets. Many healthcare systems and patients face reimbursement limitations, which dampens demand and slows revenue growth. For example, patients with chronic conditions like diabetes care may delay upgrading to digital pens due to out‑of‑pocket expenses, reducing market expansion and incentivizing preference for basic, lower‑cost alternatives.
03

Opportunity: Pediatric and needle-phobic patient segments in Japan favor painless needle-free Self Injection Devices solutions and Home-based biologics administration in North America driving advanced connected Self Injection Devices adoption

The increasing proportion of Japans elderly population along with parents who are safety conscious are increasingly looking for less stressful methods of administering drugs, thereby enhancing the potential for rapid growth in the needle free self injection devices market. Currently, adult patients receive the majority of use in allergy immunotherapy, growth hormone therapy and vaccine treatments, leaving scope for considerable expansion. Companies that modify needle free injectors for smaller dose quantities and quieter operation, and a more child friendly design, will differentiate themselves strongly from competitors. In the Asia Pacific region, Japan is expected to spearhead the growth in the use of needle free injection systems within the paediatric and the needle phobic patient centred point of care sectors.
The trend of US payers and healthcare service providers is transferring expensive treatments from a clinic to a home setting. This is driving the adoption of injectors with increased functionality. By 2030, the market value of global auto injectors is predicted to be 17.24 billion U.S. dollars from 9.46 billion U.S. dollars in 2025, with an annual growth rate of 12.74%.Significant growth is predicted for connected auto injectors and wearables which include sensors that track patient adherence, allow remote monitoring and integrate with digital health systems for the treatment of rheumatology and oncology conditions.
04

Challenge: Regulatory barriers and complex approval processes delay product commercialization

Stringent regulatory requirements and prolonged approval timelines for self injection devices, particularly those with novel features like connected sensors or combination drug‑device products, hinder market entry. These barriers inflate development costs and extend time‑to‑market, limiting competitive differentiation. For instance, companies innovating smart injection systems may face extended clinical validation and certification steps, reducing near‑term revenue potential and discouraging investment in advanced technologies amid uncertain reimbursement and regulatory landscapes.

Supply Chain Landscape

1

Component Materials

Gerresheimer AGBD
2

Self Injection Devices

YpsomedHaselmeier AG
3

Drug Delivery Integration

Antares Pharma Inc.BD
4

Home Care Applications

Diabetes careAutoimmune disease therapyHome healthcare
Self Injection Devices - Supply Chain

Use Cases of Self Injection Devices in Diabetes Management & Home Based Hormone Therapy

Diabetes Management : Self injection devices are widely used in diabetes management to facilitate insulin delivery by patients at home or in clinical settings. Prefilled insulin pens and autoinjectors are the most common devices, offering precise dosing, ease of use, and reduced injection pain management. Leading companies like Novo Nordisk, Sanofi, and Eli Lilly provide innovative insulin pens with safety features and digital integration to track dosage. Their strong market presence, patient education programs, and reliability have made them preferred choices for both patients and healthcare providers worldwide.
Vaccine Delivery : Self injection devices are increasingly adopted for vaccine administration, particularly in mass immunization programs and remote healthcare settings. Prefilled syringes and autoinjectors are the most frequently used types, ensuring accurate dosage, rapid administration, and minimal risk of contamination. Companies such as BD (Becton Dickinson), Sanofi, and Pfizer lead the market by offering reliable, user-friendly devices that enhance vaccine safety and efficiency. Their strong regulatory approvals and global distribution networks reinforce their position in both hospital and community vaccination programs.
Home Based Hormone Therapy : Self injection devices are vital in home-based hormone therapy, enabling patients to self-administer treatments such as growth hormone, fertility hormones, and testosterone. Prefilled pens and autoinjectors are primarily used, offering precise dosing, ease of handling, and reduced discomfort. Key market players including Pfizer, Ferring Pharmaceuticals, and Amgen provide devices designed for patient safety, compliance, and long-term therapy adherence. Their focus on ergonomic design and patient support services strengthens their adoption in home healthcare and specialty clinics.

Recent Developments

Recent developments in Autoinjector center on advanced prefilled autoinjectors, smart connected injection systems, and ergonomically enhanced pens that improve patient adherence and dosing accuracy. Leading manufacturers like BD (Becton Dickinson), Sanofi, and Novo Nordisk are expanding portfolios with digital dose tracking and intuitive designs to support chronic disease management and vaccine delivery programs. A key market trend is the rise of connected self-care devices with Bluetooth integration and app support, boosting remote patient monitoring and personalized treatment outcomes.

September 2025 : Ypsomed received FDA clearance for its SmartPilot connectivity add-on, transforming its YpsoMate autoinjector into a connected system that supports safer and digitally enabled self-injection guidance.
June 2025 : Ypsomed opened a dedicated production site in China, expanding manufacturing capacity in Changzhou to support global supply of self-injection systems and autoinjectors.
August 2024 : SHL Medical AG launched Elexy, a reusable electromechanical drug delivery device supporting digital therapeutics and specialty formulations, enhancing its portfolio in the connected self-injection space.

Impact of Industry Transitions on the Self Injection Devices Market

As a core segment of the Medical Device industry, the Self Injection Devices market develops in line with broader industry shifts. Over recent years, transitions such as Rise of Biologics and Shift to Patient-Centric Home Therapies have redefined priorities across the Medical Device sector, influencing how the Self Injection Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Rise of Biologics

The outlook for the market of self injection devices is set to be altered by the increasing use of biologic drugs for long term health conditions. This is due to the rise in the use of biologics and should see approximately $4 billion added to the market by the year 2030. While there is an increasing reliance on biologic therapies in the treatment of conditions such as diabetes and rheumatoid arthritis, there is a trend towards the use of self injection devices. These devices are primarily auto injectors which allow for the accurate dosing of medication outside of a hospital setting. The trend underscores the growing importance of self injection devices in chronic disease management, boosting innovation in user friendly drug delivery and home based treatment options which can improve patient adherence and outcomes. In addition to increasing market size, these developments are also altering the way companies differentiate themselves through their devices, their connectivity and how their products integrate with biologic pipelines.
02

Shift to Patient-Centric Home Therapies

Self injection devices are evolving to support home-based treatment, minimizing reliance on clinical settings for chronic or long-term therapies such as diabetes, hormone replacement, and biologics. Prefilled pens and autoinjectors with ergonomic designs, safety features, and easy usability enable patients to self-administer medications confidently. This shift has accelerated adoption in home healthcare, telemedicine, and specialty pharmacy sectors. Companies like Sanofi, Pfizer, and Ferring Pharmaceuticals have expanded product portfolios targeting self-administration, reducing healthcare facility burden and operational costs. The transition emphasizes patient empowerment, adherence, and convenience, driving demand for compact, user-friendly devices while influencing insurance coverage models and home care infrastructure.